home / stock / tak / tak news


TAK News and Press, Takeda Pharmaceutical Company Limited American Depositary Shares

Stock Information

Company Name: Takeda Pharmaceutical Company Limited American Depositary Shares
Stock Symbol: TAK
Market: NYSE
Website: takeda.com

Menu

TAK TAK Quote TAK Short TAK News TAK Articles TAK Message Board
Get TAK Alerts

News, Short Squeeze, Breakout and More Instantly...

TAK - Big pharma rally after J&J earnings

2024-07-17 14:09:20 ET More on AbbVie, Bristol-Myers, etc. Is Bristol-Myers Squibb's Rich Dividend Yield Worth The Patent Cliff Correction Risk? Johnson & Johnson (JNJ) Q2 2024 Earnings Call Transcript Don't Let The Market Fool You: Bristol-Myers Is Not A Value T...

TAK - argenx SE: A Post FDA Approval Assessment

2024-07-10 12:19:05 ET Summary argenx SE's stock is down significantly from its all-time highs due to some clinical failures for its primary asset, Vyvgart. However, recent approval for a label expansion into CIDP has turned sentiment more positive, with the shares spurting forwar...

TAK - Neurocrine's Pipeline, Including Crinecerfont's Priority Review, Drives Long-Term Growth

2024-07-09 10:32:15 ET Summary Ingrezza Sprinkle, granules, has been recently granted with the FDA approval. Supporting $2.1-2.2 billion in 2024 sales for the whole Ingrezza franchise guided by Neurocrine’s management. Neurocrine Biosciences, Inc. has two new drug applicati...

TAK - Eli Lilly Targets IBD, Takes Calculated Gamble With $3.2bn Morphic Deal

2024-07-08 12:30:52 ET Summary Eli Lilly and Company is set to acquire Morphic Holding for $3.2bn. Morphic is focused on autoimmune disease drugs. Morphic's MORF-057 has a similar MoA to Takeda's ~$5bn per annum selling drug entyvio, but it is orally available, unlike the injectab...

TAK - Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With U.S. Biopharma

2024-07-07 07:49:00 ET Summary Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. Takeda has made the initial $100 million payment to option global rights (ex-China) for olverembatinib from Ascentage Pharm...

TAK - How To Trade (TAK)

2024-07-04 20:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

TAK - Global Anti-Obesity Market Analysis: Key Trends And Insights

2024-07-04 11:30:00 ET Summary This article will present an in-depth analysis of drugs being developed to combat obesity and related diseases. Pharmaceutical companies are highly interested in the global obesity treatment market, which is expected to exceed $100 billion by 2030. ...

TAK - How To Pick Top Pharma Stocks: Novo Nordisk And More

2024-07-02 11:20:47 ET Summary This article will outline nine steps I use to identify the most promising pharmaceutical companies and avoid investment pitfalls. In addition, each of the nine steps will provide examples of various factors and how they influence the assessment of th...

TAK - Codexis to sell Pompe, Fabry assets to Crosswalk Therapeutics

2024-07-01 17:28:05 ET More on Codexis Codexis, Inc. (CDXS) Q1 2024 Earnings Call Transcript Codexis, Inc. 2024 Q1 - Results - Earnings Call Presentation Codexis GAAP EPS of -$0.16 beats by $0.02, revenue of $17.1M beats by $3.8M Codexis Q1 2024 Earnings Prev...

TAK - 3 Biotech Stocks For The Second Half Of 2024

2024-06-27 16:48:49 ET Summary The small biotech sector has badly underperformed the major market indices so far in 2024. However, that could change as the Federal Reserve cuts interest rates and/or M&A deal volume picks up across the industry. Today, we highlight three sm...

Next 10